1701 GMT - Bayer's filing to review a lower court's decision on a case alleging the company's Roundup product caused cancer is the next step forward in the litigation, Morgan Stanley analysts say. The German pharmaceutical company argues that the "failure-to-warn" claims, on which all glyphosate cases are based, are preempted by the Federal Insecticide, Fungicide, and Rodenticide Act's labeling rules, the analyst says. The Supreme Court could potentially decide on whether or not to take the case in the second quarter, with a potential final decision by end 2025 or in the first half of 2026, they say. Shares fall 1.3% to 19.83 euros. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
April 07, 2025 13:01 ET (17:01 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.